entertainment -WSS

entertainment

author：leisure time 2025-09-28 02:26:58 - browse：2

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Nearly two

hotspot

WSS

Verily hires former Apple Health leader as chief scientific officer

Second xenotransplant done with gene

For BCIs, commercial hurdles may be bigger than scientific ones

For BCIs, commercial hurdles may be bigger than scientific ones

Thermo Fisher plant for manufacturing gene therapies to expand

Emergency workers more likely to restrain Black patients: study

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

CDC advisers recommend seasonal use of Pfizer RSV shot

Moonlake's readout produced a cash windfall. Risks remain

How AI helped researchers track recovery from depression

After affirmative action ruling, medical educators look to 'holistic review'

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

State Dept. review finds Biden bears some blame for Afghanistan failures

White House drug shortage group privately met with industry

New air purifier tech could be key to improving indoor air quality

Humana, CVS hope to turn members into patients at clinics

focus

Senate HELP committee spars over health care workforce policies

STAT Virtual Event: Putting AI to the Test

Hearing on Medicare drug price negotiation gets unusually heated

Attacks on the drug industry will lead to fewer breakthroughs

How Vertex's cystic fibrosis drug is changing patients' lives

CDC's new outbreak response network to include Northeastern

entertainment

focus

hotspot

focus